持田製薬(株)の貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|
東証PRM | 医薬品 | 4534/E00947 | - |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|
2024/09/20 | 日証協 | 112,884株 | +26.51% | 231,626株 | +91.46% | 159,667株 | +29.66% | 49,804株 | +176.63% |
2024/09/13 | 日証協 | 89,232株 | +8.57% | 120,976株 | +25.67% | 123,142株 | -4.95% | 18,004株 | +49.29% |
2024/09/06 | 日証協 | 82,192株 | -31.48% | 96,268株 | -26.92% | 129,549株 | -23.16% | 12,060株 | -87.37% |
2024/08/30 | 日証協 | 119,958株 | -1.54% | 131,734株 | +0.01% | 168,599株 | +33.34% | 95,456株 | +2298.39% |
2024/08/23 | 日証協 | 121,832株 | -12.23% | 131,724株 | +2.99% | 126,447株 | -4.09% | 3,980株 | -56.64% |
2024/08/16 | 日証協 | 138,811株 | -8.92% | 127,902株 | +0.2% | 131,843株 | +0.14% | 9,179株 | -0.3% |
2024/08/09 | 日証協 | 152,401株 | -1.6% | 127,646株 | +1.39% | 131,658株 | -6.26% | 9,207株 | -19.94% |
2024/08/02 | 日証協 | 154,886株 | -0.35% | 125,900株 | -23.76% | 140,449株 | -12.62% | 11,500株 | -47% |
2024/07/26 | 日証協 | 155,424株 | -7.2% | 165,139株 | -27.55% | 160,742株 | -2.43% | 21,700株 | +53.87% |
2024/07/19 | 日証協 | 167,479株 | -17.19% | 227,927株 | +9.11% | 164,742株 | -20.2% | 14,103株 | +2.2% |
2024/07/12 | 日証協 | 202,237株 | -7.96% | 208,902株 | -33.1% | 206,436株 | -0.89% | 13,800株 | -65.09% |
2024/07/05 | 日証協 | 219,731株 | +1.78% | 312,242株 | +15.07% | 208,283株 | +2.86% | 39,526株 | +68.86% |
2024/06/28 | 日証協 | 215,882株 | +3.25% | 271,346株 | -9.51% | 202,490株 | +0.8% | 23,407株 | +11.79% |
2024/06/21 | 日証協 | 209,080株 | -3.66% | 299,873株 | +11.66% | 200,883株 | -4.85% | 20,939株 | -2.18% |
2024/06/14 | 日証協 | 217,033株 | +3.5% | 268,561株 | -26.69% | 211,112株 | +1.07% | 21,405株 | -42.02% |
2024/06/07 | 日証協 | 209,702株 | -8.43% | 366,318株 | +21.96% | 208,883株 | -8.52% | 36,916株 | -10.18% |
2024/05/31 | 日証協 | 229,017株 | +3.2% | 300,351株 | -42.17% | 228,347株 | -0.18% | 41,099株 | -3.06% |
2024/05/24 | 日証協 | 221,914株 | +20.06% | 519,350株 | +109.38% | 228,766株 | +9.48% | 42,397株 | +36.7% |
2024/05/17 | 日証協 | 184,832株 | +1.32% | 248,044株 | +77.9% | 208,958株 | -0.76% | 31,015株 | +324.86% |
※株式分割は考慮していませんのでご注意ください。
Page Top